Ankylosing Spondylitis Clinical Trial
Official title:
Open Label Clinical Trial With Rituximab (MabThera ®) in Ankylosing Spondylitis
To evaluate the efficacy and safety of rituximab when added to NSAIDs and/ or methotrexate both for TNFalpha inhibitor naïve or TNFalpha inhibitor failure patients with moderate to severe ankylosing spondylitis
Status | Unknown status |
Enrollment | 20 |
Est. completion date | November 2009 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Patients 18 – 65 years of age who have moderate to severe ankylosing spondylitis. - Active disease is defined as a BASDAI score of ³ 4 plus a - back pain score (BASDAI question 2) of ³ 4 despite concurrent NSAID therapy, or intolerance to NSAIDs - If on prednisone, £10 mg per day must be stable for 4 weeks prior to baseline. - If on methotrexate, £ 25 mg per week must be stable for 4 weeks prior to baseline - If on sulfasalazine, must be stable 4 weeks prior to basline - Women of child bearing potential must have a negative pregnancy urine test at study baseline and use an adequate, effective method of contraception (such as implants, injectables, combined oral contraceptives, some IUDs, sexual abstinence, vasectomised partner) for a duration of 12 months after stop of rituximab therapy. - Sexual active men must use an accepted method of contraception for a duration of 12 months after first administration of rituximab. - Willingness and capability to give written informed consent, written consent for data protection (legal requirement in Germany: datenschutzrechtliche Einwilligung) and willingness to participate and to comply with the study Exclusion Criteria: Exclusion criteria related to general health conditions - Patients with other chronic inflammatory articular disease or systemic autoimmune disease, e.g. Systemic lupus erythematosus,Sjögren’s syndrome, active rheumatoid vasculitis, a history of systemic diseases associated with arthritis, chronic fatigue syndrome - Any active infection, a history of recurrent clinically significant infection, a history of recurrent bacterial infections with encapsulated organisms - Primary or secondary immunodeficiency - History of cancer with curative treatment not longer than 5 years ago except basal-cell carcinoma of the skin that had been excised - A history of pulmonary or cardiac insufficiency, or serious and/or uncontrolled diseases that are likely to interfere with the evaluation of the patient's safety and of the study outcome - Evidence of significant uncontrolled concomitant diseases such as cardiovascular disease ( e.g. heart failure class III/IV NYHA, cardiac infarct within last 6 month), nervous system, pulmonary, renal, hepatic, endocrine or gastrointestinal disorders. - Neuropathy that can interfere with quality of life and/or pain assessment. - Patients with a history of a severe psychological illness or condition such as to interfere with the patient's ability to understand the requirements of the study. - History of current evidence of abuse of “hard” drugs (e.g. cocaine/ heroine) or alcoholism - Known hypersensitivity to any component of the product or to murine proteins (sodium citrate, polysorbate 80, sodium chloride, sodium hydroxide, HCl). - Women lactating, pregnant, nursing or of childbearing potential with a positive pregnancy test (urine test) - Males or females of reproductive potential not willing to use effective contraception (e.g. contraceptive pill, IUD, physical barrier) for up to 12.5 months after first infusion of rituximab - History of alcohol, drug or chemical abuse within 6 month prior to screening - Lack of peripheral venous access Exclusion criteria related to medications - Obligatory indication for initiation of established therapy, e.g. with TNFalpha-inhibitors - If on leflunomide, leflunomide must have been terminated at least 8 weeks prior to the first rituximab infusion (or = 28 days after 11 days of standard cholestyramine or activated charcoal washout). - If on TNFalpha blocking agent (infliximab, etancercept, adalimumab), the TNFa therapy must have been terminated at least 4 weeks prior to the first rituximab infusion if etanercept was used and at least 8 weeks if infliximab or adalimumab were used - Previous treatment with rituximab or intolerance to rituximab - Corticosteroids at doses exceeding 10 mg per day of prednisolone or the equivalent within the last 4 weeks prior to the first rituximab infusion - Intolerance or contraindication to drugs required for the treatment of the side effects of rituximab (e.g. paracetamol, acetaminophen, diphenhydramine, p.o. and i.v. corticosteroids, anti-emetics or H1 blockers - Previous treatment with any investigational agent - Previous treatment with i.v. immunoglobulins - Receipt of a live vaccine within 4 weeks prior to treatment - Intra-articular or parenteral corticosteroids within 4 weeks prior to screening visit Exclusion criteria related to lab findings - Haemoglobin < 8.5 g/dl - Neutrophil counts < 2.000 / µl - Platelet count < 125.000 / µl - Lower than 1 x 1000/µl lymphopenia for more than three months prior to inclusion. - Serum creatinine > 1.4 mg/dl for women or 1.6 mg/dl for men. - Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2.5 times upper limit of normal - Positive HIV, hepatitis B or C serology Exclusion criteria related to formal aspects - Patients who participate currently in another clinical trial or patients who participated in another clinical trial during the last 30 days. - Patients who are underage or patients who are incapable to understand the aim, importance and consequences of the study and to give legal informed consent (according to § 40 Abs. 4 and § 41 Abs. 2 und Abs. 3 AMG). - Patients who are institutionalised due to regulatory or juridical order (according to AMG § 40 (1) Abs. 4) |
Country | Name | City | State |
---|---|---|---|
Germany | Charite, Campus Benjamin-Franklin, Med. Clinic I, Rheumatology | Berlin | |
Germany | Rheumazentrum Ruhrgebiet, St. Josefs Krankenhaus | Herne |
Lead Sponsor | Collaborator |
---|---|
Charite University, Berlin, Germany | Hoffmann-La Roche |
Germany,
Appel H, Kuhne M, Spiekermann S, Ebhardt H, Grozdanovic Z, Köhler D, Dreimann M, Hempfing A, Rudwaleit M, Stein H, Metz-Stavenhagen P, Sieper J, Loddenkemper C. Immunohistologic analysis of zygapophyseal joints in patients with ankylosing spondylitis. Arthritis Rheum. 2006 Sep;54(9):2845-51. — View Citation
Appel H, Loddenkemper C, Grozdanovic Z, Ebhardt H, Dreimann M, Hempfing A, Stein H, Metz-Stavenhagen P, Rudwaleit M, Sieper J. Correlation of histopathological findings and magnetic resonance imaging in the spine of patients with ankylosing spondylitis. Arthritis Res Ther. 2006;8(5):R143. — View Citation
Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004 Jun 17;350(25):2572-81. — View Citation
Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, Racewicz AJ, van Vollenhoven RF, Li NF, Agarwal S, Hessey EW, Shaw TM; DANCER Study Group. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006 May;54(5):1390-400. — View Citation
Sieper J, Baraliakos X, Listing J, Brandt J, Haibel H, Rudwaleit M, Braun J. Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab. Rheumatology (Oxford). 2005 Dec;44(12):1525-30. Epub 2005 Aug 9. — View Citation
Sieper J, Braun J. Pathogenesis of spondylarthropathies. Persistent bacterial antigen, autoimmunity, or both? Arthritis Rheum. 1995 Nov;38(11):1547-54. Review. — View Citation
Zochling J, van der Heijde D, Burgos-Vargas R, Collantes E, Davis JC Jr, Dijkmans B, Dougados M, Géher P, Inman RD, Khan MA, Kvien TK, Leirisalo-Repo M, Olivieri I, Pavelka K, Sieper J, Stucki G, Sturrock RD, van der Linden S, Wendling D, Böhm H, van Royen BJ, Braun J; 'ASsessment in AS' international working group; European League Against Rheumatism. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2006 Apr;65(4):442-52. Epub 2005 Aug 26. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Evaluation in week 24 and until study end: ASAS 20 in AS patients naïve to TNFalpha inhibitors as well as in AS patients with previous therapy with TNFalpha inhibitors. | |||
Secondary | Safety Evaluations (Adverse events, vital signs, physical examination results, and clinical laboratory values until week 48) | |||
Secondary | Efficacy Evaluations: | |||
Secondary | ASAS 40 response | |||
Secondary | ASAS criteria for partial remission | |||
Secondary | Duration of response | |||
Secondary | BASDAI 20%, 50%, 70% improvement | |||
Secondary | BASFI | |||
Secondary | Mobility examinations | |||
Secondary | BASMI | |||
Secondary | Chest Wall Expansion | |||
Secondary | disease controlling antirheumatic therapy criteria (DC-ART20) (5 out of 6) | |||
Secondary | CRP, ESR | |||
Secondary | Quality of Life | |||
Secondary | SF-36Numeric Rating Scale (NRS) | |||
Secondary | physicians global | |||
Secondary | patients global | |||
Secondary | general pain | |||
Secondary | nocturnal pain Enthesitis index (Maastricht scale | |||
Secondary | swollen joint countEQ-5D | |||
Secondary | Socio-economic questionnairecourse of change of active and chronic inflammatory lesions in MRI after 24 weeks and after 48 weeksB cell analysis and T cell analysis |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02685904 -
A Multicentre Study to Evaluate the Efficacy and Safety of ENIA11 in Patients With Ankylosing Spondylitis
|
Phase 3 | |
Completed |
NCT02186873 -
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
|
Phase 3 | |
Completed |
NCT01668004 -
The Incidence of Extra-Articular Manifestations in Participants With Ankylosing Spondylitis Treated With Golimumab (MK-8259-012)
|
Phase 4 | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Completed |
NCT01934933 -
Etanercept and Celecoxib Alone/Combined Treatment in Effectiveness and Safety of Active Ankylosing Spondylitis
|
Phase 4 | |
Not yet recruiting |
NCT04875299 -
Optimal Adalimumab Plasma Concentrations in Ankylosing Spondylitis Patients
|
||
Completed |
NCT02763111 -
Clinical Trial to Evaluate Efficacy and Safety of Multiple Subcutaneous Injections of Various Doses of BCD-085 in Patients With Active Ankylosing Spondylitis
|
Phase 2 | |
Completed |
NCT02758782 -
NSAIDs Added to Anti-TNF Therapy Versus Anti-TNF Therapy Alone on Progression of Structural Damage in Ankylosing Spondylitis
|
Phase 4 | |
Active, not recruiting |
NCT02687620 -
Does Immunogenicity Have an Influence on the Efficacy of Anti-TNF Therapy in Patients With AS: An Inception Cohort Study
|
||
Completed |
NCT02154425 -
A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers
|
Phase 1 | |
Completed |
NCT01750528 -
Prevalence and Progression of Periodontitis in Ankylosing Spondylitis
|
N/A | |
Completed |
NCT01463189 -
Web-based Support to Manage Arthritis Pain
|
Phase 2 | |
Completed |
NCT01091675 -
Assessment of the Response to Etoricoxib in Patients With Ankylosing Spondylitis and Inadequate Response to ≥2 NSAIDs
|
Phase 3 | |
Completed |
NCT00844805 -
Infliximab for Treatment of Axial Spondyloarthritis (P05336 AM1)
|
Phase 3 | |
Recruiting |
NCT00747578 -
Health-Related Quality of Life and Disease-Related Costs: Comparison Between Ankylosing Spondylitis, Rheumatoid Arthritis and Systemic Lupus Erythematosus in Taiwan
|
N/A | |
Completed |
NCT01083693 -
Quality of Life Outcomes of HUMIRA in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) After Unsustainable Response to Biologicals and Disease Modifying Antirheumatic Drugs
|
N/A | |
Completed |
NCT00715091 -
Effects of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) on RAdiographic Damage in Ankylosing Spondylitis
|
Phase 4 | |
Not yet recruiting |
NCT00517101 -
Presence of IBD Specific Antibodies (ASCA, ALCA, ACCA, AMCA) in the Sera of Patients With Spondyloarthropathy
|
N/A | |
Completed |
NCT00367211 -
Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PN 200 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated Ulcers.
|
Phase 3 | |
Completed |
NCT00133315 -
TNFalfa Blocking Treatment of Spondylarthropathies
|
Phase 4 |